Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SAN FRANCISCO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) announced today that Thomas B. Neff, Chief Executive Officer and Chairman of the Board of Directors of FibroGen, passed...
-
SAN FRANCISCO, Aug. 21, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the National Medical Products Administration (NMPA) in China has approved expansion of the...
-
— On Track to Submit U.S. NDA for Roxadustat in October —— Initiated ZEPHYRUS Phase 3 Study of Pamrevlumab in IPF — Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time SAN...
-
SAN FRANCISCO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by FibroGen, Inc (NASDAQ: FGEN) we are advised by the company the “Live (U.S./Canada)”...
-
SAN FRANCISCO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that it will report second quarter 2019 financial results on Thursday, August 8, 2019 after market...
-
SAN FRANCISCO, July 24, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced publication of results from the Phase 3 trial of the efficacy and safety of roxadustat treatment...
-
-- One of Two Concurrent Publications of Roxadustat China Phase 3 Results in The New England Journal of Medicine -- SAN FRANCISCO, July 24, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN)...
-
SAN FRANCISCO, July 22, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced dosing of the first patient in the ZEPHYRUS Phase 3 clinical study of pamrevlumab in patients with...
-
SAN FRANCISCO, June 28, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that the company will present interim data on their open-label, single-arm Phase 2 trial evaluating...
-
SAN FRANCISCO, June 10, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today...